share_log

Oppenheimer Upgrades Avalo Therapeutics to Outperform, Announces $35 Price Target

Moomoo 24/7 ·  Apr 16 08:52

Oppenheimer analyst Leland Gershell upgrades Avalo Therapeutics (NASDAQ:AVTX) from Perform to Outperform and announces $35 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment